Treating the Root Molecular Cause of Osteoarthritis Is a $390B Opportunity

500M+ people live trapped by debilitating joint pain caused by osteoarthritis (OA), yet Big Pharma has failed to develop an effective treatment. Cytonics is breaking that cycle. Our next-generation biologic, CYT-108, has completed a first-in-human Phase 1 clinical trials and is now preparing to advance into Phase 1b/2a.

What makes CYT-108 different? It’s built on the same protease-inhibition pathway validated by our first-generation APIC™ therapy, which has already treated 10,000+ patients safely and effectively. That track record de-risks CYT-108 and positions it as a potential first-in-class disease-modifying therapy for OA.

We’ve already raised $25M+ from 8,000+ investors who share our vision to eradicate OA once and for all. Now, you can join us at this pivotal inflection point before the next wave of clinical milestones ahead.

Reserve your shares today and be part of rewriting the future of joint disease.